ArticleBritish journal of clinical pharmacology2007
Prioritizing children's medicines for research: a pharmaco-epidemiological study of antiepileptic drugs.
Article in British journal of clinical pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis.British journal of clinical pharmacology · 2020Pooled it
- Safety of lamotrigine in paediatrics: a systematic review.BMJ open · 2015Pooled it
- Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy.CNS drugs · 2013Pooled it
- Classification status of drugs generally used for self-medication in children: a targeted review of regulatory documents.Journal of pharmaceutical policy and practice · 2026Review
- A Study of Adverse Drug Reactions to Antiepileptic Drugs in Pediatric Epileptic Patients From North India.Cureus · 2025Article
- Prevalence of use of on-label and off-label psychotropics in the Greek pediatric population.Frontiers in pharmacology · 2024Article
- Pharmacovigilance in Pediatric Patients with Epilepsy Using Antiepileptic Drugs.International journal of environmental research and public health · 2022Article
- Serum Levels of Lipids and Selected Aminothiols in Epileptic Children-A Pilot Case-Control Study.Brain sciences · 2022Article
- Antiepileptic drug use in Italian children over a decade.European journal of clinical pharmacology · 2017Article
- Protocol for a prospective observational study of adverse drug reactions of anti-epileptic drugs in children in the UK.BMJ paediatrics open · 2017Article
- Patterns of antiepileptic drugs use in epileptic pediatric patients in Jordan.Neurosciences (Riyadh, Saudi Arabia) · 2016Observational
- Medication safety research by observational study design.International journal of clinical pharmacy · 2016Review
- Trends in Antiepileptic Drug Prescriptions for Childhood Epilepsy at a Tertiary Children's Hospital in Korea, 2001-2012.Paediatric drugs · 2015Article
- Active surveillance of visual impairment due to adverse drug reactions: findings from a national study in the United Kingdom.Pharmacology research & perspectives · 2015Article
- Mortality in children and adolescents prescribed antipsychotic medication: a retrospective cohort study using the UK general practice research database.Drug safety · 2011Article
- Article
- Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007.Drug safety · 2010Article
- Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey.BMC pediatrics · 2009Article
- An increase in the prevalence of type 1 and 2 diabetes in children and adolescents: results from prescription data from a UK general practice database.British journal of clinical pharmacology · 2009Article
- The Task-force in Europe for Drug Development for the Young (TEDDY) Network of Excellence.Paediatric drugs · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the prescribing epidemiology, in UK primary care, of newer antiepileptic drugs (AEDs) compared with conventional AEDs and to identify AEDs for further research in response to the European Medicines Agency report on epilepsy.
methodsSubjects aged 0-18 years, from the UK General Practice Research Database, who were prescribed an AED between 1993 and 2005. Prescribing prevalence and incidence, stratified by age and AED, were calculated.
resultsA total of 7721 subjects were included and 70% were prescribed one drug. Overall prescribing prevalence for all AEDs had increased by 19%. The prevalence (95% confidence interval) of newer AED prescribing had increased fivefold from 0.67 (0.58, 0.76) to 3.20 (3.03, 3.37) per 1000 person-years. Conversely, the prevalence of conventional AEDs had declined by 17% from 6.63 (6.34, 6.92) per 1000 person-years to 5.51 (5.28, 5.73). Lamotrigine had 65% of newer AED prescriptions and was the most prescribed newer drug for both the 2-11 years and 12-18 years age groups with prevalences of 1.47 and 2.55 per 1000 person-years, respectively.
conclusionsThere is a rapid increase in newer AED prescribing to children and adolescents in UK primary care, while prescribing of conventional AEDs is declining. Since 1997, the prevalence of vigabatrin has fallen, coinciding with the UK safety warnings on visual field defects. The uptake of lamotrigine, topiramate and levetiracetam is rapid and as the safety of these drugs has not been established, they should be prioritized for further research. Following concerns with vigabatrin, long-term safety surveillance of all newer AEDs is strongly recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.